Post-traumatic stress disorder

Military Roots Run Deep Through Family Care Center's Commitment to Breaking the Stigma Around Mental Health

Retrieved on: 
Thursday, November 9, 2023
Post-traumatic stress disorder, FDA, Child, Army National Guard, Adolescence, TMS, Robert Ivany, Senior counsel, Life, TRICARE, Smoking cessation, Data, OCD, Tic disorder, Mental health, United States Department of the Army, Retirement, DRS, Transcranial magnetic stimulation, United States Department of Veterans Affairs, Alaska Army National Guard, Woman, Depression, Army, Patient, Veteran, Tuskegee Veterans Administration Medical Center, Nursing

DENVER, Nov. 8, 2023 /PRNewswire/ -- Every year, approximately 200,000 active-duty servicemen and women return to civilian life. Transitions for Veterans can be especially challenging due to shifting from the collective culture of military service to a more individualized role in society. In fact, studies indicate that 44% to 72% experience high levels of stress during the transition from military to civilian life.

Key Points: 
  • It's a growing concern, and it's the reason why Family Care Center continues its work to transform mental health care through its unique understanding of the military community.
  • "Our roots in providing expanded mental health care to the armed services came from a shared sense of duty, honor and dedication."
  • Family Care Center has worked to alleviate the challenges many Veterans encounter when trying to access mental health care.
  • To learn more about Family Care Center's comprehensive mental health services or to schedule an appointment, please visit https://fccwellbeing.com or call 888-374-5066.

Recent Research Shows that Massage Therapy Helps Veterans Coping with Chronic Pain

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Veterans Health Administration, Friends, Health, Chronic pain, Complement, Alternative medicine, California Department of Industrial Relations, Shoulder, Research, Massage, AMTA, VHA, PTSD, Male, Depression, Anxiety, Pain management, CIH, Mindfulness, Pain, Frovatriptan, Veterinary medicine, Health care, Hospital, Female, Veteran

EVANSTON, Ill., Nov. 8, 2023 /PRNewswire/ -- As we honor our U.S. veterans this week, the American Massage Therapy Association (AMTA) is sharing the latest research on the many ways massage can benefit veterans.

Key Points: 
  • EVANSTON, Ill., Nov. 8, 2023 /PRNewswire/ -- As we honor our U.S. veterans this week, the American Massage Therapy Association (AMTA) is sharing the latest research on the many ways massage can benefit veterans.
  • Explore recent research, which shows that massage therapy supports the health and well-being of our U.S. veterans.
  • Explore recent research on how massage therapy supports the health and well-being of our U.S. veterans.
  • Veterans cited pain and stress reduction/relaxation as the two most frequent reasons for using these CIH approaches.1
    Female veterans experience higher rates of chronic pain, depression and anxiety in comparison to male veterans.

Ketamine can rapidly reduce symptoms of PTSD and depression, new study finds

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Patient, Ketamine, Suicide, Grammatical mood, Research, Survivor, Time, Food, Nightmare, Child abuse, Sertraline, Annals of Pharmacotherapy, Injection, Psychotherapy, Veteran, Trauma, Meta-analysis, PTSD, Disorder, Disease, Assault, LSD, Pharmacy, Population, Paroxetine, Depression, Anxiety, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Vaccine, Meat

The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.

Key Points: 
  • The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.
  • Patients receiving ketamine saw their PTSD symptoms reduced by about 25% both at one day and one week after therapy.
  • Ketamine might be an effective bridge to immediately reduce patients’ symptoms until trauma-focused psychotherapy and other antidepressants can kick in.
  • What still isn’t known
    The big unknown with using ketamine for PTSD and depressive symptoms is how often the injections are needed.

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Therapy, PTSD, Toxicity, GLP, SILO, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range.
  • In collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, the six- to eight-week non-good laboratory practice (GLP) study will include single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • “Determining the dose range that should be studied is an important step before taking a new drug candidate into a first-in-human trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.

Renowned Addiction Expert and Traumatologist Releases New Book on Addiction, Trauma, and Families

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Traumatology, Amazon, Addiction, Trauma, Family therapy, LPC, Literature

DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology. This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.

Key Points: 
  • Michael F. Barnes, Ph.D, LAC, LPC recently released a book written for families struggling with addiction and trauma called, "When The Solution Becomes The Problem: Helping Families Struggling with Addiction and Trauma".
  • DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology.
  • This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.
  • The book can be purchased on Amazon or on Dr. Barnes' website: www.drmikebarnes.com .

Unlocking Hope and Healing: The Remarkable Potential of Magic Mushrooms in PTSD Treatment

Retrieved on: 
Tuesday, November 7, 2023
Psilocybin, Post-traumatic stress disorder, Education, Hope, Prevalence, PTSD, Magic mushroom, Depression, Safety, Anxiety, Movement, Patient, Potential, Hospital, Entertainment, Dietary supplement

TEMECULA, Calif., Nov. 7, 2023 /PRNewswire-PRWeb/ -- Introducing The Magic Mushroom Delivery: A New Way to Access Nature's Healing.

Key Points: 
  • Unlocking the remarkable potential of psilocybin to alleviate PTSD symptoms and provide hope and healing.
  • One such breakthrough is the growing recognition of magic mushrooms' potential in helping individuals struggling with post-traumatic stress disorder (PTSD).
  • To learn more about"The Magic Mushroom Delivery and their mission to bring hope and healing to those with PTSD, please visit https://themagicmushroomdelivery.com/ .
  • In a world where mental health challenges continue to affect countless lives, The Magic Mushroom Delivery offers a ray of hope, unlocking the remarkable potential of magic mushrooms to help individuals on their journey toward recovery and healing.

PulteGroup’s Built to Honor® Program Presents Michigan Air Force Veteran with Keys to New Mortgage-Free Home

Retrieved on: 
Tuesday, November 7, 2023
Other Philanthropy, Construction & Property, Defense, Military, Philanthropy, Veterans, Foundation, Residential Building & Real Estate, Post-traumatic stress disorder, PulteGroup, Air Medal, Rolling Thunder, Patriot Guard Riders, VFW, Caregiver, Military personnel, Life, United States Air Force, Family, News, Veteran, Television, Multimedia, NBC, Strong Mayors, Building Homes Act, Partnership, Dexter High School (Michigan), Howl, Dexter High School, Warrior, American Legion, Nightclub, Airline, Nursing, Pulte

Celebrating its 10th anniversary, PulteGroup’s Built to Honor program recognizes and thanks returning military personnel who have been injured during their term of service.

Key Points: 
  • Celebrating its 10th anniversary, PulteGroup’s Built to Honor program recognizes and thanks returning military personnel who have been injured during their term of service.
  • This is the third Built to Honor home dedicated in Michigan.
  • The Michigan War Dog Memorial K9 Salute Team performed a 21-second howl salute dedicated to Master Sergeant Obey and all veterans in attendance.
  • “This is the third Built to Honor home awarded in Michigan to a very worthy veteran,” said PulteGroup President and CEO Ryan Marshall.

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023
Post-traumatic stress disorder, FDA, Yale School of Medicine, Opioid use disorder, Standard of care, Intelligence, Government, Public Health Service Act, White House, Dexmedetomidine, Opioid epidemic, BID, Federal Food, Drug, and Cosmetic Act, Federation, Addiction, Xylazine, Psychiatry, COWS, Recreational drug use in Kenya, Locus coeruleus, Pharmacokinetics, OUD, National Institute on Drug Abuse, NIDA, Columbia University, NIH, Safety, Public, American Journal, Minneapolis Veterans Affairs Health Care System, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Fentanyl, Bangladesh Technical Education Board, RTI International, United States Public Health Service, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

ECU Health and Acadia Healthcare Host Groundbreaking Ceremony for New Behavioral Health Hospital

Retrieved on: 
Wednesday, November 1, 2023
Mental Health, Health, Infectious Diseases, Hospitals, Physical Therapy, Other Health, Managed Care, Post-traumatic stress disorder, Science, Child, Jimmy Simpson (North Carolinian racing driver), Adolescence, Nursing, Hope, Psychiatry, Bipolar disorder, Organization, Mental health, Multimedia, ECU Health Medical Center, PTSD, Environment, Medicine, ECU Health, Medical diagnosis, Student, Partnership, Hospital, East Carolina University, William R. Brody, North Carolina Department of Health and Human Services, ECU, Acadia Healthcare, Social work, ECU Brody School of Medicine, Depression, Anxiety, Patient, Bed

ECU Health and Acadia Healthcare held a ceremony today to celebrate the start of construction on its previously announced state-of-the-art, 144-bed behavioral health hospital in Greenville, North Carolina.

Key Points: 
  • ECU Health and Acadia Healthcare held a ceremony today to celebrate the start of construction on its previously announced state-of-the-art, 144-bed behavioral health hospital in Greenville, North Carolina.
  • View the full release here: https://www.businesswire.com/news/home/20231101651362/en/
    ECU Health and Acadia Healthcare Break Ground on Construction of a New Behavioral Health Hospital in Greenville, North Carolina, with an anticipated opening in Spring 2025.
  • “We are pleased construction is underway for our new behavioral health hospital, and this moment marks another milestone in our effort to improve access to behavioral health care for the region.
  • It will be a beacon of hope for patients and families in eastern North Carolina.”
    To learn more about the partnership between ECU Health and Acadia Healthcare, visit ENCBehavioralHealth.org .

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

Retrieved on: 
Tuesday, October 31, 2023
Other Health, Research, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Science, Surgery, Biotechnology, FDA, Other Science, Health, Post-traumatic stress disorder, Rat, Analgesic, Nanotechnology, National Center for Advancing Translational Sciences, IND, Central nervous system disease, Food, NCATS, Chronic pain, Hematology, Mortality, Morphine, US Food Sovereignty Alliance, CNS, Nanoparticle, Administration, Human, Traffic barrier, Transitive dependency, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Completeness, DRF, Thermoregulation, Animal, Brain, NIH, CFA, Pain management, Drug tolerance, Dog, Pain, MET, Hypersensitivity, Bangladesh Technical Education Board, Coagulation, Central nervous system, Pharmaceutical industry

Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.

Key Points: 
  • Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.
  • The MET was developed by Nanomerics, Ltd. , a UK-based nanotechnology research and development company that has licensed its MET-LENK to Virpax.
  • The nose-to-brain MET platform protects molecules from biodegrading and enhances the bioavailability of product candidates on its transport to the brain.
  • “We are grateful to the FDA for the thorough and clear direction that was provided to us in our pre-IND meeting.